Reply to Gadkowski and Stout [4]

Clinical Infectious Diseases

Volumn 44, Issue 4, 2007, Pages 619-

  Nijland, Hanneke M J ^a   Aarnoutse, R E ^a   Ruslami, R ^b   Van Crevel, Reinout ^a,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PADJADJARAN UNIVERSITY   (Indonesia)

^c NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN;

AREA UNDER THE CURVE; BODY WEIGHT; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EXPOSURE; HUMAN; HYPERGLYCEMIA; INDONESIA; LETTER; LINEAR REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TUBERCULOSIS;

EID: 33846926093     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/511086     Document Type: Letter

References (3)

1. Gadkowski LB, Stout JE. Pharmacokinetics of rifampin. Clin Infect Dis 2007; 44:618-9 (in this issue).
2. Nijland HM, Ruslami R, Stalenhoef JE, et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis 2006; 43:848-54.
3. Field A. Regression. In: Field A, ed. Discovering statistics using SPSS for Windows. London, UK: SAGE Publications, 2000.